Rovin Capital UT ADV Grows Stock Holdings in Agilent Technologies, Inc. (NYSE:A)

Rovin Capital UT ADV grew its holdings in shares of Agilent Technologies, Inc. (NYSE:A) by 1.6% during the third quarter, HoldingsChannel reports. The firm owned 5,049 shares of the medical research company’s stock after purchasing an additional 81 shares during the quarter. Rovin Capital UT ADV’s holdings in Agilent Technologies were worth $750,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Quantbot Technologies LP acquired a new stake in shares of Agilent Technologies during the 1st quarter worth $938,000. Cetera Investment Advisers raised its holdings in shares of Agilent Technologies by 953.3% in the 1st quarter. Cetera Investment Advisers now owns 32,694 shares of the medical research company’s stock worth $4,757,000 after purchasing an additional 29,590 shares during the period. iA Global Asset Management Inc. lifted its stake in shares of Agilent Technologies by 26.2% in the 1st quarter. iA Global Asset Management Inc. now owns 21,770 shares of the medical research company’s stock valued at $3,168,000 after purchasing an additional 4,523 shares in the last quarter. Bayesian Capital Management LP purchased a new stake in shares of Agilent Technologies during the 1st quarter worth about $1,355,000. Finally, Marshall Financial Group LLC acquired a new stake in shares of Agilent Technologies in the second quarter worth $1,058,000.

Insider Activity

In other Agilent Technologies news, SVP Dominique Grau sold 9,990 shares of Agilent Technologies stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $145.00, for a total value of $1,448,550.00. Following the completion of the transaction, the senior vice president now directly owns 40,011 shares in the company, valued at $5,801,595. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, CEO Padraig Mcdonnell sold 1,958 shares of Agilent Technologies stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $145.00, for a total value of $283,910.00. Following the sale, the chief executive officer now directly owns 24,118 shares in the company, valued at $3,497,110. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Dominique Grau sold 9,990 shares of Agilent Technologies stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $145.00, for a total value of $1,448,550.00. Following the sale, the senior vice president now directly owns 40,011 shares in the company, valued at approximately $5,801,595. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 11,995 shares of company stock valued at $1,739,510.

Agilent Technologies Stock Down 2.1 %

NYSE:A opened at $136.75 on Friday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.37 and a current ratio of 1.78. The company has a market capitalization of $39.29 billion, a price-to-earnings ratio of 28.37, a price-to-earnings-growth ratio of 6.14 and a beta of 1.07. Agilent Technologies, Inc. has a one year low of $104.09 and a one year high of $155.35. The stock has a 50-day simple moving average of $139.46 and a 200 day simple moving average of $138.21.

Agilent Technologies (NYSE:A) last issued its earnings results on Wednesday, August 21st. The medical research company reported $1.32 EPS for the quarter, topping the consensus estimate of $1.26 by $0.06. Agilent Technologies had a return on equity of 25.26% and a net margin of 21.75%. The company had revenue of $1.58 billion during the quarter, compared to analyst estimates of $1.56 billion. During the same quarter last year, the firm earned $1.43 EPS. The business’s revenue was down 5.6% on a year-over-year basis. Sell-side analysts predict that Agilent Technologies, Inc. will post 5.24 EPS for the current fiscal year.

Agilent Technologies Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, October 23rd. Stockholders of record on Tuesday, October 1st were given a $0.236 dividend. The ex-dividend date of this dividend was Tuesday, October 1st. This represents a $0.94 dividend on an annualized basis and a dividend yield of 0.69%. Agilent Technologies’s payout ratio is currently 19.50%.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Stifel Nicolaus reaffirmed a “buy” rating and set a $151.00 price target on shares of Agilent Technologies in a research report on Monday, August 26th. Evercore ISI increased their target price on Agilent Technologies from $135.00 to $145.00 and gave the company an “in-line” rating in a research note on Tuesday, October 1st. Wells Fargo & Company assumed coverage on Agilent Technologies in a report on Tuesday, August 27th. They issued an “overweight” rating and a $157.00 price target for the company. Bank of America raised their price target on shares of Agilent Technologies from $140.00 to $147.00 and gave the company a “neutral” rating in a report on Thursday, August 22nd. Finally, TD Cowen boosted their price objective on shares of Agilent Technologies from $153.00 to $160.00 and gave the stock a “buy” rating in a report on Thursday, August 22nd. One analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $144.36.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.